Shares of Sophiris Bio, Inc. (NASDAQ:SPHS) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $6.60.

Several research analysts recently weighed in on SPHS shares. HC Wainwright set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a research note on Saturday, June 10th. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a research note on Thursday, June 8th. Rodman & Renshaw reissued a “buy” rating and set a $6.00 price objective on shares of Sophiris Bio in a research note on Thursday, June 1st. Finally, ValuEngine lowered shares of Sophiris Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, June 13th.

Shares of Sophiris Bio (NASDAQ:SPHS) traded up 3.33% during midday trading on Friday, hitting $2.17. 179,188 shares of the company traded hands. Sophiris Bio has a 12-month low of $1.80 and a 12-month high of $3.48. The stock’s 50-day moving average is $1.98 and its 200 day moving average is $2.34. The stock’s market capitalization is $65.34 million.

TRADEMARK VIOLATION NOTICE: “Sophiris Bio, Inc. (SPHS) Receives Consensus Rating of “Buy” from Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at

A hedge fund recently bought a new stake in Sophiris Bio stock. Mesirow Financial Investment Management Inc. acquired a new position in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned about 0.18% of Sophiris Bio at the end of the most recent reporting period. 6.01% of the stock is owned by institutional investors and hedge funds.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with's FREE daily email newsletter.